Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients - PubMed (original) (raw)
. 2012 Apr 10;19(2):197-208.
doi: 10.1530/ERC-11-0329. Print 2012 Apr.
Affiliations
- PMID: 22277193
- DOI: 10.1530/ERC-11-0329
Free article
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
Balázs Gyorffy et al. Endocr Relat Cancer. 2012.
Free article
Abstract
The validation of prognostic biomarkers in large independent patient cohorts is a major bottleneck in ovarian cancer research. We implemented an online tool to assess the prognostic value of the expression levels of all microarray-quantified genes in ovarian cancer patients. First, a database was set up using gene expression data and survival information of 1287 ovarian cancer patients downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (Affymetrix HG-U133A, HG-U133A 2.0, and HG-U133 Plus 2.0 microarrays). After quality control and normalization, only probes present on all three Affymetrix platforms were retained (n=22,277). To analyze the prognostic value of the selected gene, we divided the patients into two groups according to various quantile expressions of the gene. These groups were then compared using progression-free survival (n=1090) or overall survival (n=1287). A Kaplan-Meier survival plot was generated and significance was computed. The tool can be accessed online at www.kmplot.com/ovar. We used this integrative data analysis tool to validate the prognostic power of 37 biomarkers identified in the literature. Of these, CA125 (MUC16; P=3.7×10(-5), hazard ratio (HR)=1.4), CDKN1B (P=5.4×10(-5), HR=1.4), KLK6 (P=0.002, HR=0.79), IFNG (P=0.004, HR=0.81), P16 (P=0.02, HR=0.66), and BIRC5 (P=0.00017, HR=0.75) were associated with survival. The combination of several probe sets can further increase prediction efficiency. In summary, we developed a global online biomarker validation platform that mines all available microarray data to assess the prognostic power of 22,277 genes in 1287 ovarian cancer patients. We specifically used this tool to evaluate the effect of 37 previously published biomarkers on ovarian cancer prognosis.
Similar articles
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. Györffy B, et al. Breast Cancer Res Treat. 2010 Oct;123(3):725-31. doi: 10.1007/s10549-009-0674-9. Epub 2009 Dec 18. Breast Cancer Res Treat. 2010. PMID: 20020197 - RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B, Benke Z, Lánczky A, Balázs B, Szállási Z, Timár J, Schäfer R. Győrffy B, et al. Breast Cancer Res Treat. 2012 Apr;132(3):1025-34. doi: 10.1007/s10549-011-1676-y. Epub 2011 Jul 16. Breast Cancer Res Treat. 2012. PMID: 21773767 - Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D. Yousef GM, et al. Cancer Res. 2001 Nov 1;61(21):7811-8. Cancer Res. 2001. PMID: 11691797 - Microarray-based gene expression studies in ovarian cancer.
Chon HS, Lancaster JM. Chon HS, et al. Cancer Control. 2011 Jan;18(1):8-15. doi: 10.1177/107327481101800102. Cancer Control. 2011. PMID: 21273975 Review. - Statistical development and evaluation of microarray gene expression data filters.
Pounds S, Cheng C. Pounds S, et al. J Comput Biol. 2005 May;12(4):482-95. doi: 10.1089/cmb.2005.12.482. J Comput Biol. 2005. PMID: 15882143 Review.
Cited by
- SLC45A4 is involved in malignant progression of ovarian cancer through glycolytic metabolic reprogramming.
Xu Y, Han X, You S, Zhu W, Zhang M, Lu C, He J, Yao Q. Xu Y, et al. Sci Rep. 2024 Oct 3;14(1):23031. doi: 10.1038/s41598-024-74249-z. Sci Rep. 2024. PMID: 39363015 Free PMC article. - Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma.
Zhao J, Chang L, Tu J, Sun B, Wei X. Zhao J, et al. Evid Based Complement Alternat Med. 2022 Jun 8;2022:8748434. doi: 10.1155/2022/8748434. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 39290334 Free PMC article. - Identification of genes predicting chemoresistance and short survival in ovarian cancer.
Wang C, Chen C, Chen X, Luo J, Su Y, Liu X, Yin F. Wang C, et al. Transl Cancer Res. 2024 Aug 31;13(8):4354-4371. doi: 10.21037/tcr-23-2157. Epub 2024 Aug 6. Transl Cancer Res. 2024. PMID: 39262489 Free PMC article. - Activin levels correlate with lymphocytic infiltration in epithelial ovarian cancer.
Evans ET, Page EF, Choi AS, Shonibare Z, Kahn AG, Arend RC, Mythreye K. Evans ET, et al. Cancer Med. 2024 Sep;13(17):e7368. doi: 10.1002/cam4.7368. Cancer Med. 2024. PMID: 39248018 Free PMC article. - Bioinformatics tools and resources for cancer and application.
Huang J, Mao L, Lei Q, Guo AY. Huang J, et al. Chin Med J (Engl). 2024 Sep 5;137(17):2052-2064. doi: 10.1097/CM9.0000000000003254. Epub 2024 Jul 30. Chin Med J (Engl). 2024. PMID: 39075637 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous